{"filing":{"accession_number":"0001193125-26-391415","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-14","primary_document":"d105876d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526391415/d105876d8k.htm"},"events":[{"id":33532,"run_id":30835,"accession_number":"0001193125-26-391415","anchor_item_number":"3.03","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"summary":"Jaguar Health implemented a 1-for-15 reverse stock split effective September 17, 2026, undertaken to support compliance with Nasdaq's continued listing standards. The reverse split represents a corrective action to address prior non-compliance with Nasdaq listing requirements.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37002,"accession_number":"0001193125-26-391415","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a 1-for-15 reverse stock split effective September 17, 2026, undertaken \"in order to support the Company's compliance with Nasdaq's listing standards.\" This is a material modification to security holders' rights (Item 3.03) driven by delisting risk—the company is taking corrective action to maintain its Nasdaq listing, which is a clear signal of prior non-compliance with continued listing rules.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:11:03.409187+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37003,"accession_number":"0001193125-26-391415","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports the implementation of a reverse stock split (1-for-15) previously approved by stockholders at the April 2026 Special Meeting. The filing documents the amendment to the Certificate of Incorporation and the effective date of the split. While reverse splits can signal financial distress or delisting risk, this filing is a routine administrative implementation of a previously-approved corporate action and does not itself disclose new material adverse information—it is a governance matter involving articles of incorporation amendment that would not materially change a reasonable investor's assessment beyond what was already disclosed at the time of stockholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:11:03.409187+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37004,"accession_number":"0001193125-26-391415","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the effectuation of a 1-for-15 reverse stock split approved by stockholders at the April 2026 Special Meeting, effective September 17, 2026, to support compliance with Nasdaq listing standards. While a reverse stock split is a capital structure event with operational and governance dimensions, it does not fit neatly into the specific event-type taxonomy (not an M\u0026A activity, dilutive issuance, dividend distribution, or governance vote result). The event is material because it affects the registrant's stock structure and listing status, and would inform a reasonable investor's assessment of the company's compliance posture and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:11:03.409187+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37002,"accession_number":"0001193125-26-391415","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a 1-for-15 reverse stock split effective September 17, 2026, undertaken \"in order to support the Company's compliance with Nasdaq's listing standards.\" This is a material modification to security holders' rights (Item 3.03) driven by delisting risk—the company is taking corrective action to maintain its Nasdaq listing, which is a clear signal of prior non-compliance with continued listing rules.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:11:03.409187+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15"},{"id":37003,"accession_number":"0001193125-26-391415","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports the implementation of a reverse stock split (1-for-15) previously approved by stockholders at the April 2026 Special Meeting. The filing documents the amendment to the Certificate of Incorporation and the effective date of the split. While reverse splits can signal financial distress or delisting risk, this filing is a routine administrative implementation of a previously-approved corporate action and does not itself disclose new material adverse information—it is a governance matter involving articles of incorporation amendment that would not materially change a reasonable investor's assessment beyond what was already disclosed at the time of stockholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:11:03.409187+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15"},{"id":37004,"accession_number":"0001193125-26-391415","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the effectuation of a 1-for-15 reverse stock split approved by stockholders at the April 2026 Special Meeting, effective September 17, 2026, to support compliance with Nasdaq listing standards. While a reverse stock split is a capital structure event with operational and governance dimensions, it does not fit neatly into the specific event-type taxonomy (not an M\u0026A activity, dilutive issuance, dividend distribution, or governance vote result). The event is material because it affects the registrant's stock structure and listing status, and would inform a reasonable investor's assessment of the company's compliance posture and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:11:03.409187+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15"}]}